Incyte(US:INCY) Businesswire·2025-09-18 20:21Group 1 - Incyte has received additional FDA approval for Opzelura® (Ruxolitinib) Cream for use in children aged 2-11 with atopic dermatitis [1] - This approval expands the treatment options available for pediatric patients suffering from atopic dermatitis [1] - The approval highlights the company's commitment to addressing unmet medical needs in dermatological conditions [1] Group 2 - The FDA's decision is based on clinical data demonstrating the safety and efficacy of Opzelura® in the specified age group [1] - This marks a significant milestone for Incyte as it continues to develop innovative therapies for skin disorders [1] - The approval may positively impact Incyte's market position and revenue potential in the dermatology sector [1]